AG真人官方

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston.

Details of the event are as follows:
Date: Tuesday, August 12, 2025
Time: 1:30 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio鈥檚 website at . An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of 鈥渙ff-the-shelf鈥� gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at .

View source version on businesswire.com:

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

[email protected]

Penelope Belnap

Precision AQ

212-362-1200

[email protected]

Source: Adicet Bio, Inc.